T-cell activation requires antigen recognition through the T-cell receptor-CD3 complex together with costimulatory signaling, such as CD28 engagement, to drive T-cell expansion and effector responses.
Fauna Bio Inc. has announced the designation of a second target under its obesity discovery collaboration with Eli Lilly and ...
The BRAIN Initiative Cell Atlas Network (BICAN) consortium has built a cellular atlas of the basal ganglia, a group of deep brain structures involved in movement, learning, reward, decision-making and ...
The Korea Institute of Science and Technology and the Korea Research Institute of Chemical Technology have patented new stimulator of interferon genes protein (STING; TMEM173) agonists potentially ...
Glucocorticoids (GCs) are useful to treat several autoimmune and inflammatory disorders, but continued exposure to them is tied to systemic toxicity. Santa Ana Bio Inc. has presented data regarding ...
Commit Biologics ApS has nominated COM-002 as its first development candidate, initially targeting relapsed or refractory non-Hodgkin lymphoma and with plans to expand into several autoimmune ...
Hepatocellular carcinoma (HCC) is a major contributor to cancer-related mortality, with many therapies only exerting a modest effect on survival benefits. There is a need for medicines with superior ...
An F. Hoffmann-la Roche Ltd. and Hoffmann-la Roche Inc. patent reports new amylin receptor agonists potentially useful for the treatment of diabetes and obesity.
Simcere Pharmaceutical Group Ltd. has obtained clinical trial clearance from China’s National Medical Products Administration ...
Lexeo Therapeutics Inc. has reported data on LX-2021, a cardiotropic AAV-based gene therapy for the treatment of desmoplakin cardiomyopathy designed to restore cardiac connexin-43 (Cx43).
At the recently concluded American College of Rheumatology meeting (ACR Convergence), Forward Therapeutics Inc. presented the preclinical profile of FT-2109, an oral TNFR1 signaling inhibitor.
Artbio Inc. has discovered new drug conjugates comprising an integrin αvβ6-targeting moiety covalently linked to a radiolabeled chelating moiety potentially useful for the treatment of cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results